Extended Data Fig. 1
Cervical cancer mortality ASR % reductions (A) assuming lower screening adherenceo and (B) assuming favorable VIA triage test performance (black triangles). The dots represent reductions assuming base case assumptions for test performance and the error bars represent the reductions when assuming the best (upper range) and worst (lower range) primary test performance assumptions as described in Supplementary Table 3. oAssuming 50% attendance for routine screening (with 30% of women never attending) and 75% for adherence with treatment or follow-up visits (100% for same-day eligibility). *All positive women treated after assessment of eligibility for ablative treatment. **Triage positive referred to colposcopy. ^^VIA triage positive women treated after assessment of eligibility for ablative treatment. ^HPV 16/18 positive women treated after assessment of eligibility for ablative treatment. Women positive for HPV types other than HPV 16/18 (‘OHR’) are triaged with VIA.
